CRISPR Therapeutics Aktie
35,80
EUR
-0,40
EUR
-1,10
%
38,20
USD
+0,14
USD
+0,37
%
Werbung
CRISPR Therapeutics Aktie Analyse
26.07.19 | CRISPR Therapeutics Buy | Canaccord Adams | |
30.11.18 | CRISPR Therapeutics Buy | Needham & Company, LLC | |
15.05.18 | CRISPR Therapeutics Buy | Chardan Capital Markets | |
28.03.17 | CRISPR Therapeutics Buy | Chardan Capital Markets | |
14.11.16 | CRISPR Therapeutics overweight | Barclays Capital |
Werbung
Werbung